A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
Andreone. P P; Cursaro. C C; Gramenzi. A A; Zavagliz. C C; Rezakovic. I I; Altomare. E E; Severini. R R; Franzone. J S JS; Albano. O O; Ideo. G G; Bernardi. M M; Gasbarrini. G G
Key Findings
- Around 41% of participants on thymosin‑alpha‑1 achieved full response (ALT normalization and HBV‑DNA loss) after 6 months, comparable to interferon‑alpha’s 25% in the same period.
- Thymosin‑alpha‑1 was well tolerated; the only reported issue was mild injection‑site discomfort, unlike interferon‑alpha which has more systemic side effects.
- Both thymosin‑alpha‑1 and interferon‑alpha showed significantly higher response rates than an untreated control group, confirming antiviral activity.
Practical Outcomes
- For biohackers with chronic hepatitis B, thymosin‑alpha‑1 may offer a gentler alternative to interferon, but the evidence is limited to a small trial. It isn’t a proven, off‑the‑shelf protocol and should only be considered under medical guidance and further clinical validation.
Summary
This study shows that the synthetic peptide thymosin‑alpha‑1 can lower hepatitis B virus levels and normalize liver enzymes in people with chronic hepatitis B, doing about as well as interferon but with far fewer side effects. The research is small and still experimental, so it isn’t a ready‑to‑use DIY treatment, but it suggests a potentially safer option worth watching for those dealing with HBV.
Abstract
It has recently been shown that thymosin-alpha1(T-alpha1), a synthetic polypeptide of thymic origin, is able to promote disease remission and inhibition of hepatitis B virus (HBV) replication in patients affected by hepatitis B e antigen (HBeAg)-positive chronic active hepatitis. We evaluated the efficacy and safety of T-alpha1 treatment in patients with hepatitis B e antibody (anti-HBe) and HBV-DNA-positive chronic hepatitis. Thirty-three patients were randomly assigned to receive either T-alpha1 900 microg/m2 body surface area twice weekly (17 patients) or 5 MU of interferon alfa (IFN-alpha) three times weekly (16 patients) for 6 months. At baseline, both groups were comparable concerning age, sex, liver histology, and alanine transaminase (ALT) levels. At the end of treatment, complete response (defined as ALT normalization and HBV-DNA loss) occurred in 5 of 17 (29.4%) in the T-alpha1 group and in 7 of 16 (43.8%) in the IFN-alpha group (P = not significant). After a follow-up period of 6 months, a complete response was observed in 7 of 17 (41.2%) in the T-alpha1 group and in 4 of 16 (25%) in the IFN-alpha group (P = n.s.). Compared with the results observed in a group of 15 patients never treated with IFN-alpha and followed for 12 months, the rate of complete response was significantly higher in the IFN-alpha group at the end of therapy (1 of 15 vs. 7 of 16, respectively; P < .05) and in the T-alpha1 group at the end of follow-up (1 of 15 vs. 7 of 17, respectively; P < .05). Unlike IFN-alpha, T-alpha1 was well tolerated by all patients. The only side effect, reported by some, was local discomfort at injection sites. The results of this trial suggest that T-alpha1 is able to reduce HBV replication in patients affected by anti-HBe-positive chronic hepatitis. Furthermore, compared with IFN-alpha, T-alpha1 is better tolerated and seems to induce a gradual and more sustained ALT normalization and HBV-DNA loss. In conclusion, T-alpha1 appears to be a safe and effective alternative treatment for anti-HBe-positive chronic hepatitis. The benefit of this agent in producing long-term inhibition of HBV replication must be confirmed by future trials.
Study Information
pubmed
1996
1996-10-01T00:00:00.000Z
10.1002/hep.510240404
67
32